More states are establishing prescription drug affordability boards to assess and address the cost and affordability of prescription drugs. Learn more about what these reviews mean for you and your loved ones.
Site Search
Alongside the cystic fibrosis community, we advocate for policies and programs that promote access to highly specialized CF care and that help advance research and drug development.
In comments provided to the U.S.
CF Foundation provides comments to the U.S. Department of Health and Human Services and the Centers for Medicare and Medicaid Services responding to the 2024 Medicare Physician Fee Schedule, focusing on improving access to care through telehealth.
Partnership to Protect Coverage provides comments to the U.S. Department of Health and Human Services, the Treasury Department, and the Department of Labor on a proposed rule concerning short-term, limited-duration insurance plans.
Partnership to Protect Coverage response to request for information issued by the Treasury Department, the Consumer Financial Protection Bureau, and the Department of Health and Human Services on medical credit cards, loans, and other financial products used to pay for health care that may contribute to medical debt.
The Cystic Fibrosis Foundation and the Cystic Fibrosis Therapeutics Network sent a letter to the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research to request a meeting to discuss novel approaches to clinical trial design for cystic fibrosis nucleic acid-based therapies.
Ad hoc patient coalition provides comments to the Centers for Medicare and Medicaid Services on draft guidance related to the Medicare Prescription Payment Plan, arguing the importance of the plan in ultimately lowing the cost of prescription drugs for enrollees.
Partnership to Protect Coverage issues a statement encouraging all states to use Medicaid flexibilities to ensure patients have ample opportunity to respond to redetermination requests, and to minimize disruptions in their health coverage.
CF Foundation sends a letter to Amerigroup and New Jersey Medicaid asking the groups to update their Trikafta® eligibility criteria to reflect the recent label expansion to people with CF between ages two and five.